inhibits vascular inflammation and neointimal hyperplasia through blockade of the positive feedback loop between miR-155 and TNF-␣. Am J Physiol Heart Circ Physiol 307: H552-H562, 2014. First published June 20, 2014 doi:10.1152/ajpheart.00936.2013, a traditional Chinese medicine, has multiple vasoprotective effects, including anti-inflammation. is involved in vascular inflammation and atherosclerosis. However, a direct relationship between TXL and miR-155 in the development of vascular inflammation and remodeling had not yet been shown. The objective of the present study was to investigate whether TXL exerts an inhibitory effect on the vascular inflammatory response and neointimal hyperplasia by regulating miR-155 expression. Using the carotid artery ligation model in mice, we have shown that TXL dose dependently inhibited neointimal formation and reduced the vascular inflammatory response by inhibiting inflammatory cytokine production and macrophage infiltration. miR-155 was induced by carotid artery ligation, and neointimal hyperplasia was strongly reduced in miR-155 Ϫ/Ϫ mice. In contrast, miR-155 overexpression partly reversed the inhibitory effect of TXL on neointimal hyperplasia. In bone marrow-derived macrophages, miR-155 and TNF-␣ formed a positive feedback loop to promote the inflammatory response, which could be blocked by TXL. Furthermore, TXL increased Akt1 protein expression and phosphorylation in TNF-␣-stimulated marrow-derived macrophages, and knockdown of Akt1 abrogated the TXL-induced suppression of miR-155. In conclusion, TXL inhibits the vascular inflammatory response and neointimal hyperplasia induced by carotid artery ligation in mice. Suppression of miR-155 expression mediated by Akt1 and blockade of the feedback loop between miR-155 and TNF-␣ are important pathways whereby TXL exerts its vasoprotective effects. tongxinluo; neointimal hyperplasia; inflammation; microRNA-155; macrophage; tumor necrosis factor-␣
VASCULAR REMODELING DISEASES, such as restenosis, hypertension, and atherosclerosis, are characterized by the growth and migration of smooth muscle cells (SMCs), proliferation of endothelial cells, and the inflammatory response of macrophages. This histological remodeling results in increased media wall thickness and neointimal formation. Several microRNAs (miRs) have been identified to be involved in vascular remodeling, including miR-143/145, miR-221/222, miR-126, miR-21, and miR-155. miR-143/145 and miR-126 have been shown to be protective during vascular remodeling, whereas miR-21 may promote the cellular response that leads to neointimal formation (37) . miR-155, an inflammation-related miRNA, which is upregulated in inflammatory macrophages and in macrophages in atherosclerotic lesions (28, 29) , has both proand anti-inflammatory effects by targeting several mediators of inflammatory signaling in macrophages, such as inositol polyphosphate-5-phosphatase 1 (SHIP1), suppressor of cytokine signaling 1 (SOCS1), mothers against decapentaplegic homolog 2 (SMAD2), and transforming growth factor (TGF)-activated kinase 1/MAPKKK7 (MAP3K7)-binding protein 2 (TAB2) (2, 7, 24, 25) . In particular, miR-155 deficiency in bone marrow (BM) cells of apolipoprotein E (ApoE) Ϫ/Ϫ mice resulted in reduced lesion formation induced by disturbed flow in the carotid artery, whereas LDL receptor (LDL-R) knockout (LDL-R Ϫ/Ϫ ) mice harboring miR-155 Ϫ/Ϫ BM cells developed increased atherosclerosis after a high-cholesterol diet (12, 28) . For opposite effects of miR-155 on macrophage inflammatory reponse and atherosclerosis, the net effect of miR-155 on vascular inflammation and remodeling remains unclear.
Tongxinluo (TXL) was registered in the State Food and Drug Administration of China for treatment of angina pectoris in 1996. It is extracted, concentrated, and freeze dried from a group of herbal medicines, such as ginseng, Radix paeoniae rubra, borneol, and spiny jujuba seed, which contains multiple active components that may be responsible for its antianginal effects (20, 39) . A previous study (20) has shown that TXL reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of endothelial nitric oxide synthase (eNOS) via the PKA pathway. Moreover, TXL enhances the stability of vulnerable plaques and reduces plaque area by lowering expression of oxidized LDL-R1, matrix metalloproteinase (MMP)-1, MMP-3, NF-B, and systemic and local inflammatory factors (39) . Although anti-inflammation is one of the major mechanisms underlying the beneficial effects of TXL, it remains unclear whether anti-inflammation effects are mediated by miRs.
In this study, we investigated whether and how TXL exerts a protective effect on carotid artery ligation-induced vascular inflammation and remodeling by regulating miR-155 expression.
MATERIALS AND METHODS
Animal model and treatment. Animal housing and procedures were approved by the local Animal Care and Use Committee of Hebei Medical University. Six-to eight-week-old male wild-type (WT) C57BL/6 mice and miR-155 Ϫ/Ϫ mice (Jackson Laboratory, Bar Harbor, ME) were anesthetized with 2% isoflurane gas. The left common carotid artery was dissected and ligated near the carotid bifurcation using a 6-0 suture to induce intima formation (19) . In unligated animals, the suture was passed under the exposed left carotid artery but not tightened. TXL power was administered by intragastric administration at a low dose (0.38 g·kg Ϫ1 ·day Ϫ1 ), moderate dose (0.75 g·kg Ϫ1 ·day Ϫ1 ), and high dose (1.5 g·kg Ϫ1 ·day Ϫ1 ) beginning 3 days before ligation injury and continuing for 7, 14, or 21 days thereafter. Ligated animal without TXL treatment received vehicle (water) at an equivalent amount. At specified time points after surgery, all animals were anesthetized and perfused with cold PBS, and tissues were harvested for RNA, morphology, or histological analysis.
Morphology analysis. At 7, 14, or 21 days after carotid artery ligation, mice were euthanized and perfused with PBS for 5 min followed by 4% paraformaldehyde for 3 min through the left ventricle under physiological pressure. Carotid arteries were excised and embedded in paraffin. Four-micrometer cross-sections were prepared for hematoxylin and eosin staining, covering the area 3 mm proximal to the ligation site. The neointimal area and intima-to-media ratio were calculated using Image-Pro Plus Analyzer (version 5.1) software (Media Cybernetics, Silver Spring, MD) in a blinded manner. For each section, six random noncontiguous microscopic fields were examined.
RNA isolation and quantitative RT-PCR. Total RNA was isolated from carotid arteries and cultured BM-derived macrophages (BMMs) with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Quantitative RT-PCR for the quantification of miR-155 and primary transcript (pri-)miR-155 was performed according to the manufacturer's protocol (Applied Biosystems, Foster City, CA) in two steps using specific primers for Mus musculus (mmu-)miR-155 (assay ID: 001806) and mmu-pri-miR-155 (assay ID: Mm03306395) with RnU6b (assay ID: 001093) as a normalization control. Quantitative RT-PCR of mRNAs was performed using a Platinum SYBR Green qPCR SuperMix UDG Kit (Invitrogen). A GAPDH endogenous control was used for normalization. All real-time PCR experiments were run on a ABI 7500 FAST system, and the relative amount of transcripts was calculated using the 2 Ϫ⌬⌬Ct formula (where Ct is threshold cycle), as previously described (23) . Mouse primer sequences were as follows: GAPDH, forward 5=-CGTGTTCCTACCCCCAATGT-3= and reverse 5=-TGTCATCATACT-TGGCAGGTTTCT-3=; VEGF-A, forward 5=-GCAGGCTGCTGTAAC-GATGA-3= and reverse 5=-GCATGATCTGCATGGTGATGTT-3=; FGF-␤, forward 5=-GTCACGGAAATACTCCAGTTGGT-3= and reverse 5=-CCGTTTTGGATCCGAGTTTATACT-3=; TGF-␤, forward 5=-AAACGGAAGCGCATCGAA-3= and reverse 5=-GGGACTGGC-GAGCCTTAGTT-3=; PDGF-BB, forward 5=-AGCAGAGCCTGCTG-TAATCG-3= and reverse 5=-GGCTTCTTTCGCACAATCTC-3=; TNF-␣, forward 5=-CACCACCATCAAGGACTCAA-3= and reverse 5=-AGGCAACCTGACCACTCTCC-3=; IL-1␤, forward 5=-GCAACT-GTTCCTGAACTCAACT-3= and reverse 5=-ATCTTTTGGGGTCCGT-CAACT-3=; and IL-6, forward 5=-ACGGCCTTCCCTACTTCACA-3= and reverse 5=-CATTTCCACGATTTCCCAGA-3=.
Immunocytochemistry. Paraffin cross-sections were deparaffinized with xylene and rehydrated in a graded ethanol series, and endogenous peroxidase activity was inhibited by an incubation with 3% H2O2. Sections were blocked with 5% goat serum in PBS and incubated overnight at 4°C with primary antibodies. After a PBS wash, sections were incubated with secondary antibody at 37°C for 30 min. Immunohistochemical staining was visualized by use of a diaminobenzidine kit (Zhongshan Goldenbridge Biotechnology, Beijing, China) according to the manufacturer's instructions. Sections were counterstained with hematoxylin to visualize nuclei. Primary antibodies included anti-Mac-2 antibody (1:100 dilution, Proteintech, Chicago, IL), anti-TNF-␣ antibody (1:200 dilution, Signalway Antibody, Pearland, TX), and anti-IL-1␤ antibody (1:50 dilution, Proteintech).
Adenovirus expression vector and tail vein injection. Adenoviruses harboring a DNA fragment encompassing the mmu-miR-155 gene (AdmiR-155) were entrusted to Invitrogen. Briefly, DNA oligonucleotides encoding mmu-miR-155 (13MR0026-1F 5=-TGCTGTTAATGCTA-ATTGTGATAGGGGTGTTTTGGCCACTGACTGACACCCCTAT-CAATTAGCATTAA-3= and 13MR0026-1R 5=-CCTGTTAATGC-TAATTGATAGGGGTGTCAGTCAGTGGCCAAAACACCCCTAT-CACAATTAGCATTAAC-3=) were cloned into pcDNA6.2-GW/ EmGFP-miR, pDONR221 gateway entry vector by BP recombination reaction, and finally pAD/CMV-DEST by LR recombination reaction. WT C57BL/6 mice received a single intravenous (tail) injection (10 9 plaque-forming units) of Ad-miR-155 or Ad-null (Invitrogen) every 7 days beginning 1 day before ligation injury until 21 days.
Cell culture, adenovirus infection, and small interfering RNA transfection. BMMs were prepared as follows. Briefly, the BM was removed from the femurs and tibias of 6-to 8-wk-old male WT and miR-155 Ϫ/Ϫ mice and suspended in RPMI-1640 supplemented with 10,000 U/ml penicillin and streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 1ϫ nonessential amino acids, 50 M 2-mercaptoethanol, 10% heat-inactivated FBS, and 25 ng/ml recombinant murine colony-stimulating factor -1 (PeproTech, Rocky Hill, NJ). Cells were incubated at 37°C in a 5% CO2 incubator for 7-9 days to allow differentiation into primary macrophages. BMMs grown to 70 -80% confluence were infected by Ad-miR-155 (Invitrogen) or Ad-null (Invitrogen) at a titer of 50 plaque-forming units/cell. For small interfering (si)RNA experiments, BMMs were transfected with siRNA targeting Akt1 (GenePharma, Shanghai, China) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Nonspecific siRNA (GenePharma) was used as a control. Eight hours after transfection, cells were subjected to each experiment.
ELISA. Concentrations of TNF-␣ and IL-1␤ were determined in BMM cell culture medium using a mouse TNF-␣ ELISA kit or a IL-1␤ ELISA kit (Ray Biotech, Norcross, GA), respectively. Absorbance was measured with a microplate reader (SPECTRAFluor Plus, Tecan).
Western blot analysis. Lysates from BMMs were prepared with 150 mM NaCl, 50 mM Tris·HCl (pH 7.5), 1% Nonidet P-40, 0.5% sodium deoxycholic acid, and complete protease inhibitor mixture tablets (Roche Applied Science), and protein was then isolated. Equal amounts of protein from each sample were separated by 10% SDS-PAGE and electrotransfered to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). Membranes were blocked with 5% milk for 2 h at room temperature and incubated overnight at 4°C using the following primary antibodies: rabbit anti-phosphorylated (p-)Akt (1: 500), rabbit anti-Akt1 (1:500, Cell Signaling Technology, Beverly, MA), and mouse anti-␤-actin (1:1,000, Santa Cruz Biotechnology). Membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (1:10,000) for 2 h and then evaluated with the ECL detection system.
Statistical analysis. Data presented as bar graphs are means Ϯ SE. Differences between two groups were assessed using ANOVA followed by a Student's t-test. P values of Ͻ0.05 were considered to be statistically significant.
RESULTS

TXL inhibits neointimal hyperplasia induced by carotid artery ligation.
Morphometric analysis showed that neointimal hyperplasia was observed at 7 days after vessel ligation and was well developed by 14 days. By 21 days, the neointimal area accounted for Ͼ70% of the carotid arterial wall thickness (Fig. 1A) . Compared with the ligated group, carotid arterial wall thickness was significantly decreased in the three TXLtreated groups, and both the intima-to-media ratio ratio and intima area were lower than in the ligated group at all three time points (Fig. 1, B and C) . Moreover, the inhibitory effect of TXL on neointimal formation was more significant in moderate-and high-dose TXL groups than that in the low-dose TXL group. These results suggest that TXL dose dependently inhibits neointimal formation induced by carotid artery ligation.
TXL inhibits macrophage infiltration, vascular SMC proliferation, and inflammatory cytokine production induced by carotid artery ligation.
To assess whether the inhibitory effect of TXL on neointimal formation is related to its anti-inflammation, we determined some cytokines closely related with proinflammatory response and neointimal formation. Quantitative RT-PCR showed a significant increase in PDGF-BB, TNF-␣, and IL-1␤ mRNA in ligated vessels at 21 days after ligation, reaching 6.27-, 16.78-, and 2.07-fold above control levels, respectively. Moderate-dose TXL markedly suppressed carotid artery ligation-induced upregulation of PDGF-BB, TNF-␣, and IL-1␤ mRNA in ligated arteries ( Fig. 2A) . Next, we identified macrophage infiltration and vascular SMC (VSMC) proliferation by immunofluorescence staining. The results showed that macrophages infiltrated into the neointima of ligated arteries were readily detectable at 21 days after carotid artery ligation with proliferation of a large number of VSMCs, whereas they were barely observed in the neointima in the moderate-dose TXL-treated group, similar to unligated carotid arteries (Fig. 2B) . Consistent with mRNA expression results, protein expression of TNF-␣ and IL-1␤ as assessed by immunohistochemical staining was significantly elevated in the neointima at 21 days after ligation compared with unligated arteries, but moderate-dose TXL treatment inhibited carotid artery ligation-induced upregulation of TNF-␣ and IL-1␤ protein (Fig. 2C) ) at all three time points (1.5 mm from the ligation site), are shown. Magnification: ϫ200. B: morphometric quantification of the intima-to-media (I/M) ratio. C: morphometric quantification of the intima area. Bars represent means Ϯ SE; n ϭ 5 in each group. **P Ͻ 0.01 and ***P Ͻ 0.001 vs. unligated vessels; #P Ͻ 0.05, ##P Ͻ 0.01, and ###P Ͻ 0.001 vs. ligated vessels alone.
macrophages have infiltrated into the neointima of ligated vessels at 21 days after ligation, with an aggravation of VSMC proliferation, and that TXL treatment inhibits macrophage infiltration and VSMC proliferation and decreases the local inflammatory response induced by carotid artery ligation.
TXL suppresses miR-155 expression induced by carotid artery ligation. To examine whether the inhibitory effect of TXL on neointimal hyperplasia and macrophage inflammation is related to its regulation of miR-155, we determined the effect of carotid artery ligation on miR-155 expression and whether TXL affected the expression of miR-155 at 7, 14, and 21 days after ligation. Quantitative RT-PCR showed that miR-155 was upregulated in ligated arteries at 14 and 21 days compared with unligated vessels. Importantly, moderate-dose TXL treatment significantly suppressed the expression of miR-155 induced by carotid artery ligation (Fig. 3, A-C Ϫ/Ϫ and WT mice. As shown in Fig.  4 , A-C, marked neointimal hyperplasia was observed in ligated carotid arteries of WT mice on 21 days after ligation, which was strongly reduced in miR-155 Ϫ/Ϫ mice, suggesting that deletion of miR-155 protects against neointimal hyperplasia induced by carotid artery ligation. As expected, neointimal formation was further reduced in ligated carotid arteries of miR-155 Ϫ/Ϫ mice treated with TXL (Fig. 4 , A-C). To further define whether the inhibitory effect of TXL on neointimal formation is related to its suppression of miR-155 expression, we then introduced Ad-miR-155 into WT mice through tail vein injection to overexpress miR-155. Quantitative RT-PCR showed that miR-155 expression was increased by 3.5-fold after Ad-miR-155 injection in ligated arteries of TXL-treated mice and was barely detected in ligated arteries of miR-155 Ϫ/Ϫ mice (Fig. 4D) . Neointimal thickness was significantly increased after miR-155 overexpression regardless of TXL treatment (Fig. 4, A-C) , indicating that overexpression of miR-155 partly reversed the inhibitory effect of TXL on neointimal hyperplasia. Accordingly, macrophage infiltration and VSMC proliferation were barely observed in the neointima after carotid artery ligation in miR-155 Ϫ/Ϫ mice compared with WT mice. Meanwhile, in TXL-treated WT mice, Ad-miR-155-infected arteries showed increased macrophage infiltration and VSMC proliferation compared with Ad-null-infected arteries after carotid artery ligation (Fig. 4E) .
Next, we examined mRNA expression levels of TNF-␣ and IL-1␤ in the different groups of mice. Quantitative RT-PCR revealed that the mRNA level of TNF-␣ in ligated arteries of miR-155 Ϫ/Ϫ mice was reduced to 11% of WT mice. In TXLtreated miR-155 Ϫ/Ϫ mice, TNF-␣ mRNA levels were reduced to 20% of TXL-treated WT mice. Importantly, TNF-␣ mRNA levels were increased 2.2-fold in ligated arteries of Ad-miR-155-infected mice compared with Ad-null-injected mice regardless of TXL treatment, suggesting that miR-155 might mediate TNF-␣ mRNA expression and that miR-155 overexpression declines the inhibitory effect of TXL on TNF-␣ expression (Fig. 4F) . In contrast, although a 50% reduction of IL-1␤ mRNA was observed in ligated arteries of miR-155
mice, no significant difference in IL-1␤ mRNA levels was detected between miR-155 Ϫ/Ϫ and WT mice when these mice were treated with TXL. Moreover, after carotid artery ligation, miR-155 overexpression did not affect IL-1␤ mRNA expression in ligated arteries regardless of TXL treatment (Fig. 4G) . These results suggest that the inhibitory effect of TXL on IL-1␤ expression is not through suppression of miR-155 expression.
miR-155 and TNF-␣ form a positive feedback loop to promote the macrophage inflammatory response, and TXL blocks this feedback pathway. The macrophage inflammatory response is a key event for the initiation and progression of vascular remodeling (11, 26) . Because we found that macrophage infiltration was strongly associated with vascular inflammation induced by carotid artery ligation and that TXL could improve artery structure after ligation as well as that deletion or overexpression of miR-155 markedly affected TNF-␣ expression in ligated arteries, we sought to determine whether there was a regulatory relationship between miR-155 and TNF-␣ in the inflammatory response of macrophages. First, mouse BMMs were stimulated with TNF-␣ or IL-1␤. Quantitative RT-PCR showed that miR-155 expression was increased by 2.5-fold after TNF-␣ treatment, whereas TXL treatment suppressed the expression of miR-155 induced by TNF-␣ in a dose-dependent manner (Fig. 5A) . On the other hand, no significant upregulation of miR-155 expression was observed after IL-1␤ treatment, and TXL treatment did not significantly affect miR-155 expression (Fig. 5B) . These results suggest that TNF-␣, but not IL-1␤, can markedly induce miR-155 expression in BMMs. We next tested whether miR-155 also affected the expression of TNF-␣ or IL-1␤. Quantitative RT-PCR revealed that overexpression of miR-155 mediated by an adenoviral vector in BMMs increased the expression of TNF-␣ by sixfold over that of Ad-null-infected BMMs, whereas BMMs from miR-155 Ϫ/Ϫ mice had a much lower level of TNF-␣ expression compared with that of BMMs from WT mice (Fig. 5C) . Similarly, overexpression of miR-155 in BMMs significantly increased the release of TNF-␣ into the medium, but BMMs from miR-155 Ϫ/Ϫ mice released less TNF-␣ into the culture medium compared with WT mice (Fig.  5D ). However, overexpression or deletion of miR-155 did not affect the expression of IL-1␤ (Fig. 5, E and F) . TXL pretreatment reduced the upregulation of TNF-␣ expression induced by miR-155 overexpression, with the TNF-␣ mRNA level being reduced to 31% of the control and the TNF-␣ protein level being decreased to 78% of the control. Moreover, BMMs from miR-155 Ϫ/Ϫ mice also showed a low level of TNF-␣ expression regardless of TXL treatment (Fig. 5, G and H) . Taken together, these results suggest that miR-155 and TNF-␣ form a positive feedback loop to promote the macrophage inflammatory response in mice and that TXL has a inhibitory effect on this feedback pathway. Furthermore, pri-miR-155 expression was also upregulated after TNF-␣ treatment, whereas TXL treatment significantly suppressed the expression of pri-miR-155 induced by TNF-␣, suggesting that TXL downregulates miR-155 at the transcriptional level (Fig. 5I) .
Akt1 is required for TXL-induced suppression of miR-155 expression. Because Akt1 negatively regulates miR-155 expression in macrophages (2), we sought to determine whether TXL suppressed miR-155 expression through Akt1 signaling in BMMs. As shown in Fig. 6A , there was a slight decrease in levels of p-Akt upon TNF-␣ stimulation, but TXL pretreatment markedly increased Akt phosphorylation. Interestingly, total Akt1 also markedly increased by TXL pretreatment for 2 h, suggesting that the increased p-Akt levels may be due to the upregulation of total Akt1 protein levels by TXL pretreatment. Next, we knocked down Akt1 by transfection of BMMs with Akt1-specific siRNA and examined the effect of TXL on miR-155 expression. Akt1 knockdown abrogated the inhibitory effect of TXL on miR-155 expression induced by TNF-␣ (Fig.  6B) , indicating that TXL inhibits miR-155 expression by upregulating Akt1 in BMMs.
TXL posttreatment still inhibits neointimal hyperplasia induced by carotid artery ligation. TXL was administrated intragastrically at a moderate dose beginning 3 days after ligation injury and continued for 21 days thereafter. Morphometric analysis showed that TXL posttreatment still inhibited neointimal hyperplasia induced by carotid artery ligation, although the suppressive effect of TXL became less robust (Fig. 7,  A-C) .
DISCUSSION
The major findings of the present study were that 1) TXL dose dependently inhibited neointimal formation induced by carotid artery ligation, 2) TXL reduced the local inflammatory response in ligated vessels by inhibiting inflammatory cytokine production and macrophage infiltration, 3) miR-155 deletion protected against neointimal hyperplasia induced by carotid artery ligation and TXL exerted its inhibitory action on neointimal formation by suppressing miR-155 expression, 4) miR-155 and TNF-␣ formed a positive feedback loop to promote the macrophage inflammatory response and TXL blocked this feedback pathway, and 5) Akt1 mediated TXL-induced suppression of miR-155 expression.
Inflammation plays a key role in the development of vascular remodeling such as atherosclerosis, restenosis after angioplasty, and bypass graft failure (5, 6, 26, 33) . Intimal thickening caused by an accumulation of VSMCs and macrophages is a central feature of the vascular remodeling process (9) .
A previous study (34) has demonstrated that TXL inhibited oxidized LDL-induced maturation of human dendritic cells and secretions of IL-12 and TNF-␣ through activation of the peroxisome proliferator-activated receptor-␥ pathway. Treatment with TXL significantly reduced serum levels of monocyte chemoattractant protein-1, high-sensitivity CRP, IL-8, IL-18, MMP-1, and P-selectin and protected against plaque inflammation in an atherosclerosis rabbit model (8) . Furthermore, TXL dose dependently lowered protein expression levels of lectin-like oxidized LDL-R1, MMP-1, MMP-3, and NF-B in plaques of a rabbit model of vulnerable plaques (39) . The above findings indicate that TXL is a potent drug for antiinflammation. However, it remains unclear whether and how TXL modulates neointimal hyperplasia via inhibition of vascular inflammation.
Blood flow cessation by complete ligation of the vessel near the carotid bifurcation can produce flow-induced vascular remodeling with neointimal formation in the mouse carotid artery (19) . The reduction in shear stress increases endothelial cell apoptosis and proliferation and induces a proinflammatory phenotype characterized by adhesiveness of macrophages (1). Accordingly, low shear stress due to disturbed flow is typically found in regions of the arterial tree, such as branching points or the outer curvature of the aortic arch, which are highly susceptible for atherosclerosis (10) . In the present study, we used this model to observe the role of TXL in protecting against flow-induced vascular remodeling in the mouse and found that TXL inhibited the neointimal hyperplasia induced by carotid artery ligation regardless of pretreatment or posttreatment.
Growth factors and cytokines produced by the injured endothelium and inflammatory cells trigger the migration and proliferation of SMCs into the intima. A previous study (32) has shown that low shear stress induced by carotid artery ligation promoted TNF-␣ and IL-1 expression and neointimal hyperplasia and that mice lacking either functional TNF-␣ or IL-1 develop less neointima than WT control mice. Furthermore, increased levels of TNF-␣ preceded the migration of VSMCs into the intima in a balloon-injured rat aorta model by several days (18) . Similarly, we found that mRNA expression levels of TNF-␣ and IL-1␤ in ligated carotid arteries were significantly increased compared with those in unligated vessels. Particularly, TNF-␣ mRNA in ligated vessels at 21 days after ligation was increased 16.78-fold above the control level. Meanwhile, PDGF-BB was also elevated after ligation, which is one of the key modulators of the SMC phenotype and proliferation (38) , indicating that an increased inflammatory response in the ligated artery might also lead to a increase in growth factor secretion, which further promotes cell prolifer- ation. Our results showed that moderate-dose TXL markedly suppressed carotid artery ligation-induced upregulation of TNF-␣, IL-1␤, and PDGF-BB expression in the ligated artery. Macrophage infiltration plays a pivotal role in the pathogenesis of vascular remodeling. Systemic inactivation and depletion of macrophages by liposomal clodronate reduced neointimal hyperplasia and restenosis in hypercholesterolemic rabbits and rats (11) . Our immunohistochemistry results also confirmed that macrophages infiltrated the neointima of ligated arteries at 21 days after carotid artery ligation with proliferation of a large number of VSMCs. Meanwhile, TNF-␣ and IL-1␤ levels were also significantly elevated in the neointima at 21 days after ligation. Whereas TXL treatment inhibited macrophage infiltration, VSMC proliferation and inflammatory cytokine production were induced by carotid artery ligation. miR-155 promotes the inflammatory response of macrophages by modifying their inflammatory capacity (2, 3, 28) and is upregulated in atherosclerotic lesions of humans and mice but reduced in the circulation of patients with coronary artery disease (15, 28) . miR-155 can promote and inhibit inflammatory macrophage activation in vitro by targeting several mediators of inflammatory signaling, such as SHIP1, SOCS1, SMAD2, and TAB2 (2, 7, 24, 25) . In vivo, suppression of Bcl6 by miR-155 increases the inflammatory response in lesional macrophages and thereby promotes lesion formation (28) . On the other hand, unidirectional high shear stress upregulates miR-155 in endothelial cells in which miR-155 limits the inflammatory response to ANG II by suppressing ANG II type 1 receptors and protein C-ets-1 (41) . Furthermore, miR-155
Ϫ/Ϫ (double knockout) mice developed fewer atherosclerosis lesions in the aortic root with reduced neutral lipid content and macrophages (13) . Although miR-155 is expressed in lesional SMCs, the development of atherosclerosis was not affected in miR-155
BMMs, suggesting that miR-155 expressed in vascular cells does not play a crucial role in atherogenesis (28) . In contrast, hematopoietic deficiency of miR-155 enhanced atherosclerotic plaque development and decreased plaque stability by increased myeloid inflammatory cell recruitment to the plaque in LDL-R Ϫ/Ϫ mice (12) . The opposite effects of miR-155 on lesion formation may depend on the stage of atherosclerosis. In the present study, we found that miR-155 was upregulated in ligated arteries and that neointimal hyperplasia was strongly reduced in miR-155 Ϫ/Ϫ mice compared with WT mice, suggesting that deletion of miR-155 protects against neointimal hyperplasia induced by carotid artery ligation. These findings indicate an important role of miR-155 in mediating neointimal formation. We further defined whether the inhibitory effect of TXL on neointimal formation is related to its regulation of miR-155 expression. We found that TXL treatment significantly suppressed the expression of miR-155 induced by carotid artery ligation. Importantly, overexpression of miR-155 partly reversed the inhibitory effect of TXL on neointimal hyperplasia and macrophage infiltration. By collecting these results, we show, for the first time, a crucial role of miR-155 in neointimal formation induced by carotid artery ligation and demonstrated that TXL exerted its inhibitory action on neointimal formation partly by suppressing miR-155 expression. Interestingly, the mRNA level of TNF-␣ in ligated arteries of miR-155 Ϫ/Ϫ mice was markedly reduced compared with that of WT mice and was increased 2.2-fold in ligated arteries infected with Ad-miR-155 regardless of TXL treatment, suggesting that miR-155 can positively regulate TNF-␣ expression and that miR-155 overexpression abrogates the inhibitory effect of TXL on TNF-␣ expression. In contrast, although the mRNA level of IL-1␤ in ligated arteries of miR-155 Ϫ/Ϫ mice was reduced by 50% of WT mice, there was no significant difference between miR-155 Ϫ/Ϫ and WT mice when these mice were treated with TXL. Moreover, after carotid artery ligation, miR-155 overexpression did not affect IL-1␤ mRNA expression in ligated arteries regardless of TXL treatment. These results suggest that the inhibitory effect of TXL on IL-1␤ expression is not through suppression of miR-155 expression.
Our study in vivo implicated a potential regulatory relationship between miR-155 and TNF-␣ in the inflammatory response. Previous studies (30, 35) have shown that TNF-␣ could upregulate miR-155 expression in macrophages and endothelial cells. However, TNF-␣ levels were decreased in alcoholtreated macrophages after inhibition of miR-155, and miR-155 overexpression increased TNF-␣ production by increasing the TNF-␣ mRNA half-life in human macrophages (4, 31) . In the present study, TNF-␣ markedly induced miR-155 expression in BMMs. On the other hand, miR-155 deletion decreased, whereas miR-155 overexpression increased, TNF-␣ expression in BMMs. These results suggest that miR-155 and TNF-␣ might form a positive feedback loop to promote the macrophage inflammatory response in mice. We found that TXL treatment suppressed the expression of miR-155 induced by TNF-␣ in a dose-dependent manner and reduced the upregulation of TNF-␣ expression induced by miR-155 overexpression. These findings indicated that TXL has a inhibitory effect on this feedback pathway revealing a mechanistic role of TXL in anti-inflammation. However, IL-1␤ did not induce upregulation of miR-155 expression, and overexpression or deletion of miR-155 also did not affect IL-1␤ expression in BMMs, consistent with our results in vivo, suggesting that miR-155 has no effect on IL-1␤ expression.
Akt1 differentially regulates miRNAs, including Let-7e, miR-155, miR-181c, and miR125b, in LPS-stimulated macrophages (2) . Akt1 ablation in mice shows a proinflammatory phenotype, resulting in enhanced atherogenesis (14) . Akt1 suppression by miR-342-5p induced proinflammatory mediators, such as inducible nitric oxide synthase and IL-6, in macrophages via the upregulation of miR-155 during atherosclerosis. Moreover, upregulation of miR-155 induced by LPS/ interferon-␥ could be abolished by an miR-342-5p inhibitor but then subsequently restored by siRNA-mediated Akt1 suppression in macrophages (36) . As expected, TXL pretreatment increased Akt1 protein expression and phosphorylation in TNF-␣-stimulated BMMs, and the siRNA-mediated suppression of Akt1 abrogated the inhibitory effect of TXL on miR-155 expression induced by TNF-␣, suggesting that Akt1 is required for TXL-induced suppression of miR-155 expression.
However, TXL-mediated cardiovascular protection is not only via anti-inflammatory effect on macrophages but also via an improvement of endothelial function. For example, TXL protected palmitic acid-induced endothelial damage by initiating AMP-actived protein kinase-mediated activation of the thioredoxin antioxidant system (40) . TXL activated the JNK/ c-Jun/heme oxygenase-1 pathway to improve endothelial function in overfatigued rats (22) . Furthermore, TXL upregulated eNOS expression via the phosphatidylinositol 3-kinase/Akt/ hypoxia-inducible factor-dependent signaling pathway to promote endothelium-dependent vasodilation (21) . On the hand, genetic eNOS deficiency increases the expression of proinflammatory cytokines and macrophage infiltration in adipose tissue, ischemic muscles, and renal injuries (16, 17, 27) . On the other hand, eNOS is a direct target of miR-155 in endothelial cells (35) . Therefore, TXL-mediated protection against vascular inflammation and remodeling may be also through the eNOS pathway and subsequent reductions in macrophage infiltration.
A major limitation of the present study is the lack of characterization of the targets of miR-155 in the context of TXL treatment, which is already as a part of continuing efforts in our next project. Another limitation is that although the components of TXL are clear, the active ingredients of TXL and their interactions remain to be clarified.
In conclusion, TXL inhibits the vascular inflammatory response and neointimal hyperplasia induced by carotid artery ligation in mice. Suppression of miR-155 expression via upregulation of Akt1 and blockade of the feedback loop between miR-155 and TNF-␣ is one of the mechanisms underlying the vasoprotective effects of TXL (Fig. 8) . 
